Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Resource Type
Article
Authors
Facon, Thierry ; Kumar, Shaji K ; Plesner, Torben ; Orlowski, Robert Z ; Moreau, Philippe ; Bahlis, Nizar ; Basu, Supratik ; Nahi, Hareth ; Hulin, Cyrille ; Quach, Hang ; Goldschmidt, Hartmut ; O'Dwyer, Michael ; Perrot, Aurore ; Venner, Christopher P ; Weisel, Katja ; Mace, Joseph R ; Raje, Noopur ; Tiab, Mourad ; Macro, Margaret ; Frenzel, Laurent ; Leleu, Xavier ; Ahmadi, Tahamtan ; Wang, Jianping ; Van Rampelbergh, Rian ; Uhlar, Clarissa M ; Tromp, Brenda ; Delioukina, Maria ; Vermeulen, Jessica ; Usmani, Saad Z
Source
In The Lancet Oncology November 2021 22(11):1582-1596
Subject
Primary Research Articles
Language
ISSN
1470-2045